HC Wainwright & Co. Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raises the price target from $25 to $27.
May 09, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avadel Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with a price target increase from $25 to $27.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting a strong belief in the company's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100